Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292265 · ClinicalTrials.gov registry record · Phase 3
A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT01292265 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 3 participants.
The verdict
NCT01292265, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the changes in joint inflammation produced by Cimzia over 12 week Treatment period measured by Power/Color Doppler and Gray scale Ultrasound.
Interventions
- BIOLOGICAL Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292265
The ClinicalTrials.gov registry entry for NCT01292265 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol is the first listed.
NCT01292265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292265 about?
NCT01292265 is a clinical study titled "A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)". To evaluate the changes in joint inflammation produced by Cimzia over 12 week Treatment period measured by Power/Color Doppler and Gray scale Ultrasound.
What is the current status of trial NCT01292265?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2011-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01292265?
The interventions under investigation include: Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT01292265?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.